Cyclin-dependent-Kinase inhibitors in medulloblastoma

Medulloblastoma (MB) is a highly aggressive embryonic tumour of the cerebellum and the most common malignant brain tumour of childhood. Despite a cure rate of approximately 70-75% among children aged 3 years, MB survivors continue to pay a high price, in terms of long-term adverse sequelae, for cure.

A major drawback of the current therapy is that it fails to recognise the heterogeneity of MB patients. Detection and categorisation of this heterogeneity is of fundamental importance because a multitude of studies have shown that intrinsic differences in the molecular profiles of MBs result in substantial differences in disease manifestation and clinical outcome. Therefore, to improve cure rates among patients with molecularly aggressive MB and reduce treatment-related morbidities, a therapeutic strategy in which treatment is tailored to match these distinctions is urgently needed.

Grant Award – Studentship 2016-2017

Funding Award – £2000

Funding Awarded to – Dr Gianpiero di Leva

Research Location – University of Salford

Lead Researcher – Dr Gianpiero di Leva

Newsletter Sign Up